Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 2, 2005

View Archived Issues

ETB receptor agonist IRL-1620 modifies tumor blood flow

MAP Pharmaceuticals expands development agreement with Elan

Fimbrigal P effective in oral candidiasis model

CX-717 studied in phase IIa trials for Alzheimer's and ADHD

Phase III lupus management study of CellCept begins dosing

TargeGen selects TG-100801 for clinical development

G-CSF demonstrates neuroprotection in stroke models

IL-24's role in immune regulation

Expansion of SAINT II study of Cerovive

Antiinflammatory properties of amentoflavone mediated via inhibition of iNOS

In vivo evidence of antinociceptive effect of ERK inhibition

Tsumura and Dainippon return lercanidipine hydrochloride rights to Recordati

GTC Biotherapeutics and Scancell collaborate on SC-101

Solvay completes Fournier acquisition

End-of-phase II meeting for Puricase

Final results of Novartis' Eon Labs tender offer

CONFIRM 2 trial of PTK/ZK unlikely to show overall survival benefit

BLA filed for Myozyme in Pompe disease

Shorter course of PegIntron and Rebetol receives positive opinion in Europe

Keppra receives positive opinion in Europe

Gene therapy combined with transmyocardial revascularization improves myocardial contractility

Novel therapeutics identified for neurological disorders

PAI-1 inhibitors in early development at Wyeth for thrombotic disorders

Novel HMG-CoA reductase inhibitors for lipoprotein disorders emerge from Bristol-Myers Squibb R&D